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What a year for David Masopust. The 
36-year-old microbiologist won the 
NIH Director’s New Innovator Award 
in September, shortly after winning 
the American Society for Microbiology 
ICAAC Young Investigator Award 
and the Beckman Foundation Young 
Investigator Award. Lymphocytes hadn’t 
even crossed his mind 15 years ago. 
But after some soul searching and tapir 
tracking in Costa Rica, Masopust began 
to hone in on immunology, eventually 
joining Leo Lefrancois’ 
laboratory at the Univer-
sity of Connecticut. There, 
he charted the migratory 
patterns of memory T cell 
populations in peripheral 
tissues after infection (1). 
He then delved deeper 
into the nature of immuno-
logical memory in Rafi 
Ahmed’s laboratory at Emory University 
in Georgia before moving to his current 
position as Assistant Professor at the 
University of Minnesota.
Memory T cell endurance can deter-
mine whether or not repeated exposure 
to a pathogen results in calamity. Masopust 
is trying to figure out what makes virus-
specific CD8  +   T cells tire or malfunc-
tion, and in doing so he’s helped discover 
ways to reverse T cell exhaustion (2). 
Masopust's portfolio is filled with studies 
on memory T cell responses after vacci-
nation and mucosal infection (3, 4). And 
although he’s not the type to say it himself, 
his body of work on CD8  +   T cells will 
undoubtedly contribute to the next wave 
of vaccination strategies.
What are tapirs and how did you fi  nd 
them?
[Laughing] Tapirs are large mammals. 
Some people describe them as a cross 
between a pig and an elephant because 
they have a semi-prehensile snout that can 
uproot small trees. Actually, they’re related 
to rhinos and weigh 300 pounds easy.
I used to help a field biologist track 
tagged tapirs with radiotelemetry. Basi-
cally, I’d go out alone in the jungle in the 
middle of the night, triangulate two 
signals, interpolate those directions, and 
get an idea of where a collared tapir 
was. It involved crossing a river in a 
rowboat with holes in it—sharks and 
caimans all around.
Did anything scary ever happen?
Once I was charged by a tapir while I was 
sort of snoozing against a fallen tree. One 
tapir had been chasing another out of its 
territory. After the smaller tapir leaped 
into the water, the bigger one turned its 
eyes toward me and seemed to say, "Why 
don’t you get out of here, too." I escaped, 
but it was intimidating! I really felt out of 
my element in the jungle. Nothing bad 
happened to me, but a guy I worked with 
was mauled by a puma one night.
Did your tapir-tracking experience 
inspire you to become an immunologist?
Not really. After I graduated college, I 
just felt that I needed to investigate what 
made me happy, so I went to Central 
America and took on a variety of random 
jobs down there.
How did you move from tapir tracking 
to graduate school?
It had to do with a wedding. I was be-
ginning to feel that fi  eld research wasn’t 
for me, and then I suddenly had to leave 
Costa Rica because my stepsister was 
getting married in the US. I read Laurie 
Garrett’s book, The Coming Plague, which 
really got me interested in infectious 
disease. Then I met Leo Lefrancois, and 
his laboratory ultimately became a great 
fi  t for me.
THE FUTURE OF MEMORY
Did you imagine you’d be so successful?
I went to graduate school thinking that 
I’d be lucky if I got a degree at the end. 
If I had thought about it more, maybe 
I wouldn’t have done it, because this is a 
tough career path. But I didn’t think about 
it, and therefore I wasn’t afraid to fail.
What do you think is a hot area of 
immunology for young investigators to 
enter now?
I think the fi  eld needs to really start con-
sidering the pathogenesis of organisms. 
People should also investigate how the 
quantity and quality of memory T cells 
are regulated, how they relate to protec-
tion against real-world infections, and 
how they can be manipulated or exploited. 
I think a lot of the focus right now is 
on dissecting why some eff  ector T cells 
become memory cells, and I’m afraid that 
the point can get lost. The point is 
learning how to protect a host against 
real-world infections.
What are you doing to get closer to actual 
problems in humans?
Although we’ve been doing reductionist 
experiments in small animal models, 
instead of just ending every paper by 
stating the implications for vaccines and 
blah, blah, blah, we’ve been trying to test 
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our assumptions. For example, rather than 
suggesting that CD8  +   T cells can pre-
vent chronic HIV infections, we are try-
ing to test that directly. What if every 
CD8  +   T cell in your entire body was 
specifi  c for HIV? What would happen 
then? I’m a fan of bold, extreme questions. 
And even though this experiment [with 
SIV in primates] won’t give us a vaccine, 
it could at least tell us that it’s possible 
to prevent this infection with memory 
CTL [cytotoxic T lymphocytes].
What topic do you think will win the next 
Nobel Prize in Physiology and Medicine?
I’m hesitant to guess about prizes in gen-
eral, but I think the next Nobel awarded 
to immunology will go to a technique 
that can turn on a protective immune 
response or turn off   a destructive response. 
That’s the Holy Grail of adaptive immu-
nity. Or it will be awarded for a prevent-
ative HIV vaccine. In general, I’m hopeful 
about vaccine development.
BOY IN A BUBBLE
Do you worry that people in the vaccine 
fi  eld rely too heavily on model systems?
Yeah, I worry a little bit. There’s a culture 
of safety fi  rst, and that’s reasonable because 
you don’t want to endanger human beings. 
But too much safety constrains what one 
thinks is possible. I think that’s why some 
approaches that have not succeeded are 
often repeated with minor refi  nements. 
Part of the problem is that there’s a limited 
pool of money, and a lot of what is funded 
tends to fall into a narrow range of accept-
able risk. I think people expect a degree of 
novelty, but they also want a certainty that 
whatever you’re doing is going to work. 
And that’s troubling because it forces 
people to do safe science, and science 
shouldn’t be safe. Well, some of it should be 
safe, but some should push the envelope.
If smallpox was a problem today, 
and you were proposing the current cow-
pox vaccine, one has to wonder if you 
could ever get far enough in your research 
to demonstrate effectiveness.
You’ve helped discover a way to revive 
exhausted CD8  +   T cells with antibodies 
that block the interaction of the inhibitory 
PD-1 receptor and its ligand. Are you 
sure exhaustion should be 
blocked therapeutically?
I may be in the minority 
here, but I’m skeptical. Ex-
haustion happens for a rea-
son. It’s an evolved response, 
which means it may have to 
do with the longevity of the 
host. Let’s say the liver cells 
in your body were infected 
with a virus and your immune 
system went about killing 
all of them, then you’d no 
longer have a liver. So even 
if you got rid of the infec-
tion, you’d be in trouble. I 
think one has to be careful 
with these kinds of therapies, particu-
larly when they are blunt and target every 
exhausted  cell. The saving grace with 
the PD-1 blockade therapy may be that 
it’s not very eff  ective by itself. If it were 
combined with something that focused 
on an antigen of interest, like in thera-
peutic vaccination, it would be more 
appealing to me. Still, you’re playing a 
dangerous game.
You helped overturn the dogma that the size 
of the memory T cell compartment was 
fi  xed. What’s the implication of this result 
and why hadn’t this been recognized before?
I think it means we can be far bolder in 
terms of generating a CD8  +   T cell vac-
cine (5). There are also academic issues 
to explore about the maintenance and 
longevity of effector memory CD8  +   
T cells. We have clues now that some 
types of memory T cells aren’t playing 
by the same rules as traditional memory 
T cells. Part of why this hadn’t been 
recognized before was because of the 
way experiments had been designed. 
You take a laboratory mouse that’s lived 
a pristine life in a cage and then give it 
one infection and study that response. 
But that approach doesn’t capture the 
complexity of the real world. People 
talk about how humans and mice are so 
divergent, but immunological experi-
ence can be vastly diff   erent within a 
species. If you catch a mouse in a barn 
and look at the fi  ngerprint of its im-
mune response, it’s night and day com-
pared with a laboratory mouse. That’s 
actually a fun little side project we’re 
doing in the laboratory—catching mice 
in a barn and looking at their immune 
systems. I got tired of studying these 
laboratory mice, these boys in a bubble. 
What happens if they eat Taco Bell 
scraps and get Salmonella and breathe 
city air?
So you track mice, too?
Luckily it’s much easier than tracking 
tapirs.
Are you familiar with David Masopust of 
the Masopust Polka Band in Oklahoma?
I am aware of him. I found 
him by “Googling” my name. 
Actually, my father called 
him once to say hi because 
my father is also named 
David Masopust.
What did he say?
Nothing. He wasn’t excited, 
or at least not as excited as 
my father was. I toyed with 
the idea of asking the David 
Masopust Polka Band to play at my 
wedding, but I changed my mind. I don’t 
think my friends are down for polka.
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Memory CD8  +   T cells can be isolated from various organs 
in LCMV-immune mice.
“What 
happens if 
[lab mice] 
eat Taco Bell 
scraps and 
get Salmonella 
and breathe 
city air?”